Dec. 2, 2025 — At RSNA 2025, Siemens Healthineers announced Syngo.CT Coronary Cockpit1, a new software solution within the Syngo.via2 platform designed to support the management of coronary artery disease (CAD) for both dual-source and photon-counting CT scanners. As the leading cause of death globally and a major contributor to disability,3 CAD continues to pose a significant global health challenge. This drives increasing demand for diagnostic and treatment planning tools that are both efficient and minimally invasive.

Dec. 2, 2025 — Brainomix, a provider of AI-powered imaging tools in stroke and lung fibrosis, has announced the publication of a prospective real-world study demonstrating that its AI imaging platform, Brainomix 360 Stroke, significantly increased rates of endovascular thrombectomy (EVT) treatment, a minimally invasive surgical procedure for patients with large vessel occlusion stroke, and reduced delays in patient triage and transfer.

CT-First Gains Momentum

More than 1 million patients undergo a cardiac catheterization each year,1 but those numbers could decline as more cardiologists look toward coronary computed tomographic angiography (CCTA) as the first test to diagnose coronary artery disease (CAD).
Tags
CCTA

Dec. 1, 2025 — Cleerly, a provider of AI-based cardiovascular imaging, will showcase new product updates at RSNA 2025. At Booth #8039, Cleerly will demonstrate PowerScribe integration and newly added lesion-level reporting, discuss new clinical research findings, and provide guidance on the plaque analysis Category I CPT code effective Jan. 1, 2026.

Nov. 30, 2025 — KA Imaging Technology has announced that its Reveal 35C detector with SpectralDR technology will be featured in two scientific presentations at the Radiological Society of North America (RSNA) annual meeting in Chicago, Ill.

The abstracts, led by independent investigators, explore the potential role of dual-energy chest X-ray in cardiac imaging applications:

Dec.1, 2025 – MannKind Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted the sNDA seeking approval for FUROSCIX ReadyFlow Autoinjector (SCP-111), developed to deliver a subcutaneous furosemide injection in less than 10 seconds as an investigational alternative to the FDA-approved FUROSCIX (furosemide) On-body Infusor for treatment of edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD). The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2026.

Nov. 24, 2025 — InspireMD, Inc., developer of the CGuard Prime carotid stent system for the prevention of stroke, welcomes the recent presentation and publication of CREST-2 data which demonstrated positive clinical outcomes for carotid artery stenting (CAS) for patients with asymptomatic carotid stenosis. CREST-2 data was shown at The Society of Vascular and Interventional Neurology (SVIN) Annual Meeting and the Vascular and Endovascular Issues Techniques and Horizons (VEITH) Symposium on Nov. 21, 2025.

Nov. 19, 2025 — Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were announced as part of the late-breaking sessions at the American Heart Association Scientific Sessions in New Orleans. The CeleBrate study of zalunfiban (Disaggpro), from CeleCor Therapeutics, met its efficacy and safety endpoints in the treatment of STEMI (heart attack) patients.

Nov. 18, 2025 — RapidAI announced U.S. Food and Drug Administration (FDA) clearance of Aortic Management, part of the Rapid Aortic product, a comprehensive deep clinical AI solution designed to transform the acute assessment and longitudinal management of aortic disease.

Nov. 18, 2025 — Harrison.ai has launched its CE-marked CT Chest solution, a comprehensive AI tool that assists clinicians in detecting 167 radiological features, including those that may be suggestive of life-threatening conditions, tumors, and chronic diseases.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now